Cancer Chemotherapy and Pharmacology

, Volume 69, Issue 2, pp 333–339 | Cite as

Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors

  • B. Schultheis
  • G. Kummer
  • M. Zeth
  • E. Brendel
  • C. Xia
  • M. Kornacker
  • D. Strumberg
Original Article

Abstract

Purpose

Sorafenib (BAY 43-9006), a multikinase inhibitor, has been shown to inhibit tumor growth and tumor angiogenesis by targeting Raf kinase, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor. This study investigated the safety, pharmacokinetics, and preliminary efficacy of sorafenib in combination with gemcitabine and cisplatin.

Methods

Patients with advanced solid tumors were treated with 75 mg/m2 cisplatin on day 1 and 1,250 mg/m2 gemcitabine on days 1 and 8 of each 21-day cycle. On day 5 of cycle 1, sorafenib 400 mg twice daily was started and continued throughout the complete treatment cycles without interruption.

Results

Nineteen patients were valid for safety analysis. The most frequent toxicities related to the cytotoxic agents were hematological disorders. Sorafenib-related toxicities were skin-related, gastrointestinal, and constitutional symptoms. No clinically relevant pharmacokinetic drug–drug interaction between sorafenib, cisplatin, and gemcitabine was detected. AUC0-72 and C max of total and unbound platinum were only marginally changed by concomitant sorafenib. Concomitant sorafenib increased mean AUC and C max of gemcitabine by 12 and 21%.

Conclusions

Sorafenib as continuous oral treatment in combination with gemcitabine and cisplatin demonstrated an acceptable safety profile. No clinically relevant pharmacokinetic interaction was detected. Preliminary antitumor activity, pharmacokinetic, and safety data support the recommendation of 400 mg sorafenib twice daily in combination with cisplatin and gemcitabine to be further evaluated in clinical studies.

Keywords

Phase I Sorafenib Gemcitabine Cisplatin Multiple kinase inhibitor Pharmacokinetics 

References

  1. 1.
    Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099–7109. doi: 10.1158/0008-5472.CAN-04-1443 PubMedCrossRefGoogle Scholar
  2. 2.
    Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27(36):6251–6266. doi: 10.1200/JCO.2009.23.5622 PubMedCrossRefGoogle Scholar
  3. 3.
    D’Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2010) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v116–v119. doi: 10.1093/annonc/mdq189 PubMedCrossRefGoogle Scholar
  4. 4.
    Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, Garcia M, Lianes P, Montalar J, Vadell C, Gonzalez-Larriba JL, Nguyen B, Artal A, Rosell R (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17(1):12–18PubMedGoogle Scholar
  5. 5.
    Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian lung cancer project. J Clin Oncol 17(11):3522–3530PubMedGoogle Scholar
  6. 6.
    Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24(24):3946–3952. doi: 10.1200/JCO.2005.05.1490 PubMedCrossRefGoogle Scholar
  7. 7.
    Sun S, Schiller JH, Spinola M, Minna JD (2007) New molecularly targeted therapies for lung cancer. J Clin Invest 117(10):2740–2750. doi: 10.1172/JCI31809 PubMedCrossRefGoogle Scholar
  8. 8.
    Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O’Dwyer PJ (2008) A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14(15):4836–4842. doi: 10.1158/1078-0432.CCR-07-4123 PubMedCrossRefGoogle Scholar
  9. 9.
    Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K, Hilger RA, Scheulen ME, Christensen O, Brendel E, Schwartz B, Hofstra E, Voigtmann R, Seeber S, Strumberg D (2005) Results of a phase I trial of sorafenib (BAY 43–9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 5(3):188–196PubMedCrossRefGoogle Scholar
  10. 10.
    CTCAE (2006) National Cancer Institute Common Terminology of Adverse Events v3.0. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf
  11. 11.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. european organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRefGoogle Scholar
  12. 12.
    Gatzemeier U, Eisen T, Santoro M, Pazzola A, Bennouna J, Liao M, Strauss UP, Montegriffo E, Ong TJ, Biesma B (2010) Sorafenib (S) + gemcitabine/cisplatin (GC) vs GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC): phase III NSCLC research EXperience Utilizing Sorafenib (NExUS) trial. 35th ESMO Congress, Milan, Italy. Ann Oncol 21(Supplement 8):viii7 (abstract)Google Scholar
  13. 13.
    Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, De Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28(11):1835–1842. doi: 10.1200/JCO.2009.26.1321 PubMedCrossRefGoogle Scholar
  14. 14.
    Scagliotti G, Govindan R (2010) Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist 15(5):436–446. doi: 10.1634/theoncologist.2009-0225 PubMedCrossRefGoogle Scholar
  15. 15.
    Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991. doi: 10.1056/NEJMoa060570 PubMedCrossRefGoogle Scholar
  16. 16.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957. doi: 10.1056/NEJMoa0810699 PubMedCrossRefGoogle Scholar
  17. 17.
    Kim ES, Herbst RS, Lee JJ, Blumenschein Jr GR, Tsao A, Alden CM, Tang X, Liu S, Stewart DJ, Heymach JV, Tran HT, Hicks ME, Erasmus J Jr, Gupta S, Powis G, Lippman SM, Wistuba II, Hong WK (2010) The BATTLE trial (biomarker-integrated approaches of targeted therapy for lung cancer elimination): personalizing therapy for lung cancer. Oral presentation at the plenary session of the AACR 101st Annual Meeting, Washington, USAGoogle Scholar
  18. 18.
    Smit EF, Dingemans AM, Thunnissen FB, Hochstenbach MM, van Suylen RJ, Postmus PE (2010) Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. J Thorac Oncol 5(5):719–720. doi: 10.1097/JTO.0b013e3181d86ebf01243894-201005000-00021[pii] PubMedCrossRefGoogle Scholar
  19. 19.
    Kelly RJ, Rajan A, Force J, Keen C, Cao L, Yu Y, Choyke PL, Turkbey B, Raffeld M, Xi L, Steinberg SM, Wright JJ, Lopez-Chavez A, Kummar S, Guttierrez M, Giaccone G (2011) Evaluation of KRAS mutations, angiogenic biomarkers and DCE-MRI in patients with advanced non-small cell lung cancer receiving sorafenib. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-10-2331

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • B. Schultheis
    • 1
  • G. Kummer
    • 1
  • M. Zeth
    • 1
  • E. Brendel
    • 2
  • C. Xia
    • 3
  • M. Kornacker
    • 4
  • D. Strumberg
    • 1
  1. 1.Department of Haematology and Medical OncologyUniversity of Bochum (Marienhospital Herne)HerneGermany
  2. 2.Bayer HealthCare PharmaceuticalsWuppertalGermany
  3. 3.Bayer HealthCare PharmaceuticalsMontvilleUSA
  4. 4.Bayer HealthCare PharmaceuticalsBerlinGermany

Personalised recommendations